Orchid Pharma Limited is a prominent Indian pharmaceutical company, established on July 1, 1992, with its headquarters in Chennai. Founded as an export-oriented unit (EOU), Orchid Pharma has evolved into a vertically integrated entity, covering the entire pharmaceutical value chain from discovery to delivery. The company possesses established credentials in research, manufacturing, and marketing. Orchid Pharma Limited operates as a subsidiary of Dhanuka Laboratories Limited.
Recognized as a significant player in the Indian pharmaceutical landscape, Orchid Pharma ranks among the top 50 pharmaceutical companies in India. As of 2024, it was also counted among the top Fortune 500 Indian companies by market capitalization. The company extends its reach globally, exporting its products to approximately 40 countries.
Orchid Pharma is dedicated to the development and manufacture of Active Pharmaceutical Ingredients (APIs) and finished dosage forms. The company's core business revolves around Cephalosporins-based APIs, which are predominantly utilized in anti-bacterial, antibiotic, and anti-inflammatory formulations.
The company boasts globally recognized manufacturing infrastructure. Orchid's state-of-the-art API facilities, located in Chennai, are approved by the USFDA, EDQM, and PMDA. Notably, Orchid Pharma maintains its distinguished position as India's sole USFDA-approved facility for Sterile Cephalosporins, underscored by successful recent inspections.
Orchid Pharma Limited is actively involved in the development, manufacture, and marketing of a comprehensive range of pharmaceutical products, including active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals within India. Its API product portfolio encompasses oral cephalosporins, injectable cephalosporins, veterinary products, and non-antibiotics.
The company has a multi-therapeutic presence spanning anti-infectives, anti-inflammatory, central nervous system, cardiovascular segments, nutraceuticals, and other oral and sterile products. Furthermore, Orchid Pharma offers novel drug discovery systems and pharmaceutical research and development services.
Orchid Pharma holds the unique distinction of being the only Indian pharmaceutical company to have discovered a New Chemical Entity (NCE), Enmetazobactam, which has received approvals in the United States, Europe, and India. The company continues to prioritize investment in research and development, accelerating its proprietary drug discovery business. This includes the development of several additional hits and leads in therapeutic areas such as inflammation, oncology, diabetes, and anti-infectives.
As of May 27, 2025, Orchid Pharma Ltd (ORCHPHARMA) holds a market capitalization of ₹3759.55 Crore. The company has demonstrated consistent financial performance with notable revenue growth.
- Revenue Growth: Sales increased by 12.52% to Rs 921.93 crore for the year ended March 2025, compared to Rs 819.37 crore in the previous year ended March 2024.
- Profit Performance: For the full year, net profit saw an increase of 8.13% to Rs 99.66 crore for the year ended March 2025, up from Rs 92.17 crore in the previous year ended March 2024.
- Revenue: Sales rose by 9.39% to Rs 237.48 crore in the quarter ended March 2025, compared to Rs 217.10 crore in the corresponding quarter of the previous year ended March 2024.
- Net Profit: Net profit for Orchid Pharma declined by 32.37% to Rs 22.29 crore in the quarter ended March 2025, from Rs 32.96 crore in the previous quarter ended March 2024.
The company's current valuation metrics include:
- P/E Ratio: The Price-to-Earnings (P/E) ratio of Orchid Pharma Ltd (ORCHPHARMA) stands at 37.73.
- P/B Ratio: The Price-to-Book (P/B) ratio is 3.21.
- 52-Week Range: The 52-week high for Orchid Pharma Ltd (ORCHPHARMA) is ₹1997.40, and the 52-week low is ₹684.35.
- Approval Received: Orchid Pharma shareholders have overwhelmingly approved the amalgamation scheme with Dhanuka Laboratories, with over 97% of votes cast in favor. This strategic consolidation is expected to bolster the company's standing in the pharmaceutical sector and provide access to enhanced resources and capabilities.
- USFDA Inspection Success: Orchid Pharma announced the successful completion of a surprise U.S. Food and Drug Administration (USFDA) inspection at its Active Pharmaceutical Ingredient (API) manufacturing facility in Alathur, Tamil Nadu. The inspection, conducted from February 10-18, 2025, resulted in seven minor observations, none of which related to the data integrity of the facility.
Orchid Pharma is proud to announce a sublicense agreement with GARDP for the manufacture of cefiderocol, an antibiotic used to treat certain Gram-negative infections. This collaborative effort with Shionogi, GARDP, and CHAI aims to provide a global solution for accessing this critical antibiotic in areas of significant need.
Orchid Pharma's unwavering commitment to addressing global healthcare challenges positions it favorably for future growth opportunities in both domestic and international markets. The company's steadfast focus on quality manufacturing, stringent regulatory compliance, and strategic partnerships continues to drive its expansion within the competitive pharmaceutical industry.
